When women had one or two copies of the SNP for a more active CYP1B1 plus two copies of the SNP for a less active COMT, they were three times more likely to have ovarian cancer, and had approximately twice the ratio of estrogen-DNA adducts to estrogen metabolites and conjugates as women without the SNPs. This evidence concerns the gene COMT and ovarian carcinoma.